Key clinical point: Nivolumab and ipilimumab combined provide superior progression-free and overall survival compared with nivolumab or ipilimumab alone.
Major finding: At 4-year minimum follow-up the median overall survival with the combination had not be reached, vs. 36.9 months for nivolumab and 19.9 months for ipilimumab.
Study details: Randomized phase 3 trial of 945 patients with previously untreated stage III or IV malignant melanoma.
Disclosures: Dr. Hodi has received grant/research support from, and is a nonpaid consultant to, Bristol-Myers Squibb, which supported Checkmate 067. Dr. Dummer reported advising/consulting roles with the company.
Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9.
This Week's Must Reads
RNA expression offers potential biomarker in hemophilia A, Niloofar N et al. Hematology. 2019;24(1):255-62
Caplacizumab speeds platelet normalization, Scully M et al. N Engl J Med. 2019 Jan 9. doi: 10.1056/NEJMoa1806311
Remote area of Canada provides pool for genetic research, Scully M-F et al. Transfus Apher Sci. 2018 Dec;57(6):713-6
Can web tools replace pharmacokinetic analysis in hemophilia A?, Nagao A et al. Thromb Res. 2019 Jan;173:79-84
BSH issues recommendations for glucocorticoid use in ITP, Hill QA et al. Br J Haematol. 2019 Jan 4. doi: 10.1111/bjh.15735
Must Reads in Immuno-oncology
Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392
NGS may ID SCLC candidates for immunotherapy, SITC 2018
Monalizumab + cetuximab is active in advanced SCC of the head and neck, Cohen R et al. SITC 2018, Abstract 051
Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514
Checkpoint inhibitor combo continues to show benefit for advanced melanoma, Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9